New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
05:59 EDTARIA, TWCStocks with implied volatility below IV index mean; TWC ARIA
Stocks with implied volatility movement; Time Warner Cable (TWC) 24, ARIAD (ARIA) 107 according to iVolatility.
News For TWC;ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
07:34 EDTARIAUBS to hold a symposium
Subscribe for More Information
July 31, 2015
10:02 EDTTWCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:23 EDTTWCTime Warner Cable downgraded to Neutral from Buy at Buckingham
Subscribe for More Information
08:06 EDTTWCTime Warner Cable price target raised to $219 at Wunderlich
Wunderlich analyst Matthew Harrigan raised his price target for Time Warner Cable to $219 citing a "high confidence" that the takeover by Charter (CHTR) will win regulatory approval. The analyst's 2016 floor value as a standalone entity is $187 per share. He keeps a Buy rating on Time Warner Cable.
07:19 EDTTWCFCC Commissioners Pai, O’Rielly 'dismayed' by delay in Charter-TWC review
Subscribe for More Information
July 30, 2015
09:13 EDTTWCTime Warner Cable says it continues to 'embrace' over-the-top video offerings
Subscribe for More Information
08:57 EDTTWCTime Warner Cable sees Q3 adjusted OIBDA down up to $100M
Subscribe for More Information
08:52 EDTTWCTime Warner Cable expects positive video net additions in FY15
Subscribe for More Information
07:31 EDTTWCTime Warner Cable reports Q2 Residential customer relationships of 14,782
Subscribe for More Information
07:30 EDTTWCTime Warner Cable reports Q2 Business Services revenue $803M
Subscribe for More Information
07:30 EDTTWCTime Warner Cable reports Q2 Residential revenue $4.76B
The growth in residential high-speed data revenue was the result of growth in high-speed data subscribers, as well as an increase in average revenue per subscriber primarily due to increases in prices and equipment rental charges and a greater percentage of subscribers purchasing higher-priced tiers of service. Residential video revenue decreased due to a year-over-year decline in video subscribers, partially offset by an increase in average revenue per subscriber primarily as a result of price increases, higher transactional video-on-demand revenue and growth in premium network revenue. Residential voice revenue decreased due to lower average revenue per subscriber offset, in part, by growth in voice subscribers.
07:29 EDTTWCTime Warner Cable reports Q2 residential video net declines of 45K
Subscribe for More Information
06:06 EDTTWCTime Warner Cable reports Q2 adjusted EPS $1.54, consensus $1.81
Subscribe for More Information
July 29, 2015
15:08 EDTTWCNotable companies reporting before tomorrow's open
Subscribe for More Information
07:47 EDTARIAARIAD to receive $200M through syntehtic-royalty financing with PDL BioPharma
Subscribe for More Information
07:43 EDTARIAARIAD to receive up to $200M through Iclusig synthetic-royalty financing with PDL BioPharma
ARIAD Pharmaceuticals (ARIA) announced that it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional $50 million in one year – through a synthetic-royalty financing from PDL BioPharma (PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig until PDL receives a fixed internal rate of return. ARIAD also has an option, in its discretion, to receive up to an additional $100 million at any time between 6 and 12 months from the date of the agreement, in one or two tranches on comparable terms. ARIAD intends to use the base funds to conduct a front-line trial of brigatinib, its investigational ALK inhibitor, in patients with non-small cell lung cancer and to support brigatinib commercial readiness, as well as to continue its ongoing Iclusig initiatives. ARIAD is on track to complete enrollment in the pivotal ALTA trial of brigatinib in third quarter 2015, to file for approval in the U.S. next year, and subject to regulatory approval, to launch brigatinib by early 2017. Brigatinib has Breakthrough Designation from the U.S. Food and Drug Administration. “This financing allows us to accelerate initiation of the front-line trial of brigatinib and to ensure launch readiness as early as possible, while retaining strategic flexibility with respect to partnering and long-term commercialization of brigatinib,” said Harvey J. Berger, M.D., chairman and CEO of ARIAD. “We are confident based on the latest clinical data on brigatinib and other ALK‐inhibitors, that brigatinib may be an important new cancer medicine for patients with ALK+ lung cancer. With the funding provided by this royalty transaction, we expect to start the front-line trial by early next year, ahead of our expected filing for initial marketing approval of brigatinib in patients with refractory ALK+ NSCLC.”
July 23, 2015
17:07 EDTTWCSoroban Capital Partners reports 5% passive stake in Time Warner Cable
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use